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Background: The overall survival of patients with esophageal squamous cell carcinoma (ESCC) remains poor.
Prognostic predictions in ESCC are usually based on histological assessment of tumor invasion and lymph node
metastasis, but a biomarker with better predictive accuracy could be more useful. Because overexpression of
epidermal growth factor receptor (EGFR) has been associated with poor prognosis, this study investigated whether
EGFR is an independent prognostic factor for overall survival and disease-free survival of ESCC patients.
Methods: ESCC tissue specimens from 243 patients obtained during surgical resection between 1980 and 1997
were retrieved for immunohistochemical analysis of EGFR expression.
Results: The data showed that EGFR protein was overexpressed in 187 of 243 (77%) ESCC tissues. Elevated
expression was associated with higher pathologic tumor stages (P = 0.001), lymph node metastasis (P = 0.002), and
higher Union for International Cancer Control (UICC) stage (P <0.0001), as well as poorer disease-free survival and
overall survival of ESCC patients (P <0.0001). A multivariate analysis showed that overexpression of EGFR protein
was an independent factor for disease-free survival (P = 0.003) and overall survival (P = 0.001) of these patients.
Subgroup analysis of patients with stage IIA (UICC 2002) showed that EGFR overexpression was associated with
poorer disease-free survival (P = 0.007) and overall survival (P = 0.010) of the patients in univariate analyses.
Conclusions: The current study demonstrated that EGFR overexpression was an independent prognostic factor
for overall survival and disease-free survival of ESCC patients. However, targeting of EGFR activity using gefitinib
or erlotinib could be useful for clinical treatment of ESCC patients.
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Fiducial markersBackground
Esophageal cancer is a significant worldwide health prob-
lem, the sixth most frequent cause of cancer death [1,2].
Surgery remains the primary treatment, but in most
cases diagnosis is not determined until after surgery is* Correspondence: xiaozefen@sina.com; prof.hejie@263.com
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reproduction in any medium, provided the orfeasible. Depending on the type of surgery, the five-year
survival rate is 15% to 37.8% [3,4]. Studies have shown
that prognosis is affected by the number of metastatic
lymph nodes [5-7]. Post-surgery pathological studies
have confirmed this and have also confirmed an inverse
association between survival and the depth of tumor
invasion [8,9].
Predictions of post-surgery prognosis are usually based
on the Union for International Cancer Control (UICC)/
American Joint Committee on Cancer (AJCC) clinical
staging system [8,9]. However, determination of tumor
stage in esophageal cancer is often imprecise making sur-
vival of patients difficult to predict, especially those in thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biomarkers for predicting survival and treatment response
in esophageal cancer.
Elevated levels of epidermal growth factor receptor
(EGFR), or increased expression of the EGFR gene, have
been reported in a number of human cancers of epithe-
lial origin, including head and neck [10], thyroid [11],
breast [12], and colon [13,14] cancers. In a subset of these
cancers, most notably breast [15], colorectal [13,14], and
esophageal cancers [16,17], increased EGFR expression has
been associated with advanced disease, tumor metastases,
and poor prognosis.
In developed countries, two-thirds of esophageal can-
cers are adenocarcinoma, but in most of the world,
including China, 95% are esophageal squamous cell
carcinoma (ESCC) [1,2,18]. In the current retrospective
study of cases occurring between 1980 and 1997 at
Cancer Hospital, Chinese Academy of Medical Science,
we investigated whether EGFR can serve as an inde-
pendent prognostic factor for overall and disease-free
survival of ESCC patients. Associations between EGFR
expression in ESCC tissue specimens and patients’ follow-
up data were analyzed.
Methods
Study population
In this retrospective cohort study, we retrieved the
medical records of 243 patients who had undergone
esophagectomy for ESCC, without any pre-surgical neo-
adjuvant or adjuvant chemotherapy or chemoradiotherapy,
between 1980 and 1997 at Cancer Hospital, Chinese Acad-
emy of Medical Science. These patients had a clinically lo-
calized ESCC, including 23, 92, 68, 28, and 32 patients
with stage IB, II, IIIA, IIIB, and IIIC disease, respectively,
based on the definitions of the UICC 2010 version [9].
Paraffin-embedded tissue specimens were retrieved from
the Pathology Department and prepared for construction
of tissue microarray and cut into 4 μm-thick sections for
immunohistochemistry.
As reported previously [5], for tumor in the upper
third of the thoracic segment surgeons performed a
three-phase thoraco-abdominal McKeown resection via
a right thoracotomy, using the stomach for esophageal
replacement. For lesions in the mid and lower third,
esophagectomy was performed on the left side using the
stomach to establish digestive continuation. In each case,
lymph nodes were removed as completely as possible.
Juxtatumoral, paraesophageal, superior gastric, left gas-
tric, and paracardial lymph nodes were analyzed indi-
vidually to determine a final stage classification based on
the 2002 and 2010 International Union against Cancer
system.
A total of 4,160 lymph nodes (median, 17; range, 0 to 49)
were dissected for pathologic staging of the disease afterhistological examination of hematoxylin-eosin stained tis-
sue sections.
The Institutional Review Board of Cancer Hospital,
Chinese Academy of Medical Science approved this study.
All patients or their guardians signed an informed consent
form to participate in this study. The patients were
followed-up regularly every 3 to 6 months after surgery
or until death. The last follow-up was in December
2010, which included an esophagograph, chest radio-
graph, and ultrasound scan of the liver. Treatment failure
was defined as any local or distant morphologic evidence
of tumor.
For patients with tumor recurrence, treatments in-
cluded any methods considered useful for relief of suf-
fering. Until the end of follow-up, 77 patients had
regional recurrence, and only 35 patients underwent sal-
vage treatment (surgery, 10; radiotherapy, 25). Forty-one
patients had organ metastasis; only 12 patients under-
went salvage chemotherapy. The median duration of the
follow-up time was 25 months (range, 6 to 280 months)
after the esophagectomy; the mean duration was 36
months. Five patients were lost at the last follow-up. We
counted these as deceased and there was no censure
when we calculated overall survival (OS) and disease-free
survival (DFS).
Immunohistochemistry
Tissue microarray sections were deparaffinized in xylene
and rehydrated in an ethanol series to water. Antigen re-
trieval was performed in a citrate buffer (0.01 M, pH 6.0)
with a microwave-based method. After incubation with
20% normal serum, the sections were incubated with
an anti-EGFR antibody (Novocastra, Cat: #NCL-EGFR-
384, Newcastle Upon Tyne, UK) in a humidified chamber
overnight at 4°C. The next day, the sections were washed
with phosphate buffered saline (PBS) three times, and
further incubated using the PV-9000 Polymer Detection
System (GBI Labs, cat: #PV-9000, Mukilteo, WA, USA)
and color-reacted with 3,3′-diaminobenzidine (DAB) so-
lution (Zhongshan cat# ZLI-9018, Beijing, China) as a
chromogen.
Two experienced pathologists who were blinded to
the clinical data reviewed the stained tissue sections.
At least five microscopic fields were evaluated. The
sections were scored for EGFR expression semiquanti-
tatively based on the color and the percentage of epi-
thelial cells showing membrane staining. The intensity
was classified as follows: 0, negative staining; 1, weak
staining; 2, moderate staining; 3, strong staining. The
percent of positive cells was recorded as: 1, 0 to 25%;
2, 26 to 50%; 3, 51 to 75%; 4, >75%. A final score was
achieved by multiplying the intensity (0, 1, 2, or 3) and the
percent of positive cells (1, 2, 3, or 4). For data analysis,
scores <8 were defined as ‘low expression’ (Figure 1A),
Table 1 Patient demographics, clinicopathological features,
and epidermal growth factor receptor (EGFR) expression
EGFR -Total EGFR- Low EGFR- High P valuea
N % n % N %
Gender 0.130
Male 176 77.0 45 80.4 131 70.1
Female 67 23.0 11 19.6 56 29.9
Age (y) 0.675
<40 12 4.9 4 7.17 8 4.3
41 to 50 56 23.0 15 26.8 41 21.9
51 to 60 101 41.6 21 37.5 80 42.8
60 to 68 74 30.5 16 28.6 58 31.0
Length (cm) 0.730
≤5.0 130 53.5 32 57.1 98 52.4
5.1 to 7.0 90 37.0 20 35.7 70 37.4
>7.0 23 9.5 4 7.1 19 10.2
Tumor location 0.137
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(Figure 1B).
Statistical analysis
Categorical data were compared using the chi-squared
test. The Kaplan-Meier method was used to construct
OS and DFS curves, and the log-rank test was used to
determine the statistical significance of differences.
DFS was computed from the time of surgery to the
time of clinical diagnosis of recurrent tumor, or death
without evidence of disease recurrence, at which point
the data were censored. OS was calculated from the
time of surgery to the time of death from any cause,
or to the time of last follow-up, at which point the
data were censored. The prognostic significance of
clinical and pathologic characteristics was determined
using univariate Cox regression analysis. To assess the
presence of possible confounding variables, a Cox re-
gression model for multivariate analysis was appliedUpper 33 13.6 5 5.9 28 15.0
Middle 155 63.8 42 75.0 113 60.4
Lower 55 22.6 9 16.1 46 24.6
Histological differentiation 0.607
Well 93 38.3 21 37.5 72 38.5
Moderate 124 51.0 27 48.2 97 51.9
Poor 26 10.7 8 14.3 18 9.6
Tumor invasion 0.001
T2 31 12.8 13 23.2 18 9.6
T3 168 69.1 41 73.2 127 67.9
T4 44 18.1 2 3.6 42 22.5
Lymph node status 0.002
- 130 53.5 40 71.4 90 48.1
+ 113 46.5 16 28.6 97 51.9
Number of LNM 0.024
1 to 2 65 57.5 8 50.0 57 58.8
3 to 6 39 34.5 4 25.0 35 36.1
≥7 9 8.0 4 25.0 5 5.2
Pathological stage (UICC, sixth edition) <0.0001
IIA 110 41.3 39 69.6 71 38.0
IIB 8 5.0 3 5.4 5 2.7
III 125 51.4 14 25.0 111 59.4
Pathological stage (UICC, seventh edition) 0.002
IB 23 9.5 10 17.9 13 7.0
IIA 87 35.8 29 51.8 58 31.0
IIB 5 2.1 1 1.8 4 2.1
IIIA 68 28.0 7 12.5 61 32.6
IIIB 28 11.5 4 7.1 24 12.8
IIIC 32 13.2 5 8.9 27 14.4
aP, P values were calculated by using chi-square.
Figure 1 Immunohistochemical detection of epidermal growth
factor receptor (EGFR) protein expression in esophageal
squamous cell carcinoma (ESCC) tissues. Paraffin-embedded
tissue sections were processed for immunohistochemical analysis of
EGFR expression, which was semiquantitatively scored. (A) Low and
(B) high EGFR expression.
Figure 2 Association of epidermal growth factor receptor (EGFR)
expression with overall and disease-free survival of patients using
Kaplan-Meier curves and the log-rank test. (A) Overall survival and
(B) disease-free survival.
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analysis. All statistical analyses were performed using
SPSS software (version 13.0 for Windows; SPSS, Chicago,
IL, USA). Kaplan-Meier survival curves were drawn with
GraphPad Prism (version 5.0 for Windows; GraphPad
Software, San Diego, CA, USA). A 2-sided significance
level of P <0.05 was considered statistically significant.
Results
Expression of epidermal growth factor receptor protein in
esophageal squamous cell carcinoma tissue specimens
We retrieved tissue samples from each of the 243 ESCC
patients and immunostained these tissue sections for
EGFR expression. Our data showed that in 187 of the
243 cases (77.0%) high levels of EGFR protein were ob-
served in ESCC tissues, while in the remaining cases
EGFR levels were nil or low. We then investigated corre-
lations between EGFR expression and clinicopathological
data from the patients and found that EGFR expression
was associated with advanced tumor stage (P = 0.001),
tumor lymph node metastasis (P = 0.002), and higher
pathological stages (UICC 2002 and 2010, P <0.001).
However, EGFR expression was not associated with age,
gender, tumor location, size of the tumor lesion, or
histological differentiation (Table 1).
Association of epidermal growth factor receptor expression
with overall survival of esophageal squamous cell
carcinoma patients
We investigated correlations between EGFR expression in
resected ESCC tissues and survival of ESCC patients and
found that the 5-year OS and DFS rates of patients with
EGFR expression were 15.0% and 14.4%, respectively, and
the median survival times were 16.0 months and 11.6
months. In contrast, the 5-year OS and DFS rates for pa-
tients with no or low EGFR expression in ESCC tissues
were 39.3% and 37.5%, respectively, and the median sur-
vival times were 31.7 and 25.7 months (Figure 2A,B). The
differences in OS and DFS between these two groups are
statistically significant (P < 0.0001, both).
Univariate and multivariate analysis of overall survival
and disease-free survival of esophageal squamous cell
carcinoma patients
To identify the important prognostic factors for ESCC, we
performed univariate and multivariate analyses. The uni-
variate analysis data showed that tumor size, pathological
tumor stage, positive lymph nodes, tumor-node-metastasis
(TNM) stage (UICC, sixth or seventh edition), and EGFR
expression all affected the OS and DFS of the patients
(Table 2). The multivariate analysis further showed that
histological grade, positive lymph nodes, tumor size and
EGFR expression were independent prognostic factors for
OS and DFS of these patients (Table 3).Subgroup analyses of epidermal growth factor receptor
expression and overall survival of patients
To further confirm the usefulness of EGFR as a prognos-
tic factor, we compared subgroups of patients who tested
either negative or positive for metastasis in lymph nodes
(130 and 113 patients, respectively). In the negative lymph
node group, the 5-year OS (DFS) rate was 28.9% (24.0%)
in patients who expressed EGFR, and 50.0% (47.5%) for
patients with low levels or no EGFR expression (P = 0.002
(P = 0.001)). However, in the 113 cases with positive
lymph nodes, the 5-year OS rates were 5.2% for patients
with high EGFR expression, and 12.5% for those with low
expression (P = 0.067).
For the 110 patients with stage T2-3N0M0 IIA dis-
ease (2002 UICC), the 5-year OS (DFS) rate was
29.6% (28.0%) for those with high-EGFR expression,
and 48.7% (46.7%) for those with low-EGFR expres-
sion (P = 0.010 (P = 0.007)). Furthermore, in 87 cases
of patients with stage T3N0M0 IIA (UICC seventh
edition) disease, the 5-year OS rate for patients with
high EGFR expression was significantly lower than
those with low EGFR expression (29.3% compared with
48.3%; P = 0.026).
Table 2 Univariate analysis of disease-free survival (DFS) and overall survival (OS) of esophageal squamous cell
carcinoma (ESCC) patients
N Disease-free survival Overall survival
HR 95% CI P value HR 95% CI P value
Gender
Male (ref) 176 1 1
Female 67 1.202 0.894 to 1.616 0.222 1.223 0.906 to 1.650 0.188
Age (y) 0.154 0.178
<40 (ref) 12 1 1
41 to50 56 0.531 0.265 to 1.066 0.075 0.559 0.278 to 1.121 0.101
51 to 60 101 0.720 0.500 to 1.037 0.078 0.716 0.496 to 1.035 0.075
60 to 68 74 0.857 0.631 to 1.164 0.324 0.875 0.643 to 1.190 0.395
Length (cm) 0.008 0.011
≤5.0 (ref) 130 1 1
5.1 to 7.0 90 0.546 0.345 to 0.864 0.100 0.563 0.356 to 0.890 0.014
>7.0 23 0.762 0.477 to 1.218 0.256 0.781 0.488 to 1.248 0.301
Tumor location 0.104 0.204
Upper (ref) 33 1 1
Middle 155 1.611 1.029 to 2.520 0.037 1.502 0.961 to 2.349 0.075
Lower 55 1.280 0.925 to 1.772 0.136 1.166 0.842 to 1.615 0.354
Histological differentiation 0.012 0.325
Well 93 1 1
Moderate 124 1.418 1.064 to 1.891 0.017 1.296 0.972 to 1.727 0.077
Poor 26 1.271 1.059 to 1.526 0.010 1.247 1.039 to 1.497 0.018
EGFR expression
Low (ref) 56 1 1
High 187 1.974 1.413 to 2.758 <0.0001 2.075 1.485 to 2.899 <0.0001
Tumor stage <0.0001 <0.0001
T2 (ref) 31 1 1
T3 168 1.303 0.874 to 1.940 0.192 1.320 0.886 to 1.967 0.170
T4 44 1.468 1.146 to 1.880 0.002 1.532 1.194 to 1.965 0.002
N stagea
N0 (ref) 130 1 1
N1 113 2.203 1.676 to 2.897 <0.001 2.267 1.723 to 2.983 <0.001
Stagea <0.0001 <0.0001
IIA (ref) 110 1 1
IIB 8 1.343 0.650 to 2.776 0.640 1.253 0.607 to 2.585 0.541
III 125 1.539 1.336 to 1.771 <0.0001 1.583 1.373 to 1.824 <0.0001
N stageb <0.0001 <0.0001
N0 (ref) 130 1 1
N1 65 1.833 1.339 to 2.509 <0.0001 1.882 1.374 to 2.578 <0.0001
N2 39 1.682 1.384 to 2.044 <0.0001 1.756 1.442 to 2.138 <0.0001
N3 9 1.701 1.338 to 2.161 <0.0001 1.532 1.210 to 1.940 <0.0001
Stageb <0.0001 <0.0001
IB (ref) 23 1 1
IIA 87 0.969 0.596 to 1.576 0.899 0.939 0.577 to 1.529 0.801
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Table 2 Univariate analysis of disease-free survival (DFS) and overall survival (OS) of esophageal squamous cell
carcinoma (ESCC) patients (Continued)
IIB 5 0.971 0.590 to 1.599 0.908 0.908 0.555 to 1.486 0.702
IIIA 68 1.283 1.082 to 1.523 0.003 1.289 1.086 to 1.529 0.003
IIIB 28 1.386 1.168 to 1.644 <0.0001 1.433 1.203 to 1.708 <0.0001
IIIC 32 1.280 1.123 to 1.458 <0.0001 1.306 1.145 to 1.489 0.967
HR, hazard ratio; CI, confidence interval; P value was calculated by using a log-rank test; ref, reference.
aUICC, sixth edition.
bUICC, seventh edition.
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EGFR overexpression has been reported previously in 40
to 84% of esophageal cancer tissues [19-21]. Significant
associations have been found between the level of EGFR
expression and some clinicopathological characteris-
tics, including tumor differentiation, tumor stage, lymph
node status, and UICC TNM stages [19,22,23]. However,
whether or not EGFR expression is associated with the sur-
vival of esophageal cancer patients remains controversial.
Several researchers have shown that EGFR overexpression
was associated with poor OS and DFS of esophageal cancer
patients [22-24], whereas others have demonstrated that
EGFR overexpression had no association with either sur-
vival rates [25,26]. These inconsistent conclusions drawn
from different studies may be due to an insufficient num-
ber of cases or duration of follow-up, or the methods used
to detect EGFR expression.
In the present study, we retrospectively retrieved
ESCC tissue specimens from 243 patients, which had
been collected from 1980 to 1997, and followed these pa-
tients for more than 13 years. Moreover, with these speci-
mens we performed standard immunohistochemistry using
an anti-EGFR monoclonal antibody from Novocastra,
an international company with an excellent reputation for
providing immunohistochemistry-quality antibodies, to
provide more informative data. We found that EGFR pro-
tein was highly expressed in 77% of these tissue speci-
mens. High EGFR expression was associated with tumor
invasion, lymph node metastasis, numbers of lymph node
metastases, and UICC 2002 and 2010 TNM stages in these
esophageal cancer patients. These data are consistent withTable 3 Multivariate Cox regression analysis of disease-free s
Overall survival
HR (95% CI)
Histological grade 1.804 (1.282 to 2.540)
Tumor stage 1.191 (0.797 to 1.778)
Lymph node status 2.028 (1.529 to 2.688)
EGFR expression 1.804 (1.282 to 2.504)
Tumor size (length) 1.331 (1.090 to 1.625)
HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor.previous studies [19,22,23]. More importantly, OS and DFS
rates were significantly lower in patients with high EGFR
expression than in patients with little or no EGFR expres-
sion. Further multivariate analysis showed that EGFR ex-
pression is an independent prognostic factor for ESCC
patients. A future study will investigate how the EGFR sig-
naling pathway contributes to esophageal cancer progres-
sion or chemotherapy resistance in ESCC patients.
Until now, pathological features of ESCC such as tumor
stage, lymph node status, and tumor distant metastasis
have been widely used as prognostic or chemotherapy indi-
cators in addition to more detailed subgroup staging. The
latter staging system may better predict prognosis since it
is not uncommon that prognosis differs even in patients
with the same clinical stage. For instance, the 5-year OS
rate of patients with stage IIa disease (according to UICC
2002, T2-3N0M0) after esophagectomy was about 50%,
and the remaining patients died within five years because
of tumor recurrence or metastasis. Rice et al. [7] showed
that the 5-year OS rate was about 60% for T2N0M0
esophageal cancer and about 50% for T3N0M0, a dif-
ference that is statistically significant. Subsequently,
stage IIa disease (UICC 2002), which includes T2N0M0
and T3N0M0, was changed to Ib (T2N0M0) and IIa
(T3N0M0) in the UICC 2009 edition.
In the current study the 5-year OS rates of T2N0M0 and
T3N0M0 diseases were 39.1% and 35.6%, respectively, a
difference that was not statistically significant (P = 0.801).
However, in the same group of patients, the levels of EGFR
expression (that is, high levels compared with low) signifi-
cantly influenced both the 5-year OS and DFS rates. Thisurvival (DFS) and overall survival (OS)
Disease-free survival
P value HR (95% CI) P value
0.062 1.301 (1.060 to 1.597) 0.012
0.394 1.178 (0.790 to 1.758) 0.422
<0.0001 1.888 (1.423 to 2.504) <0.0001
0.001 1.681 (1.192 to 2.369) 0.003
0.005 1.334 (1.093 to 1.627) 0.005
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precise tool for prediction of survival of esophageal cancer
patients. Use of EGFR expression could contribute to sta-
ging and a more accurate prognostic prediction compared
with UICC staging alone, especially for patients with stage
T2/T3N0M0. Furthermore, our current multivariate ana-
lysis showed that EGFR expression and lymph node status
were independent prognostic factors to predict survival of
esophageal cancer patients, whereas tumor stage was not
able to predict survival. These results suggest that tumor
stage alone was not as sensitive as EGFR and lymph node
status in predicting the prognosis of patients.
EGFR is the cell-surface receptor for members of the
epidermal growth factor family. It is activated by binding
to its specific ligands, including epidermal growth factor
(EGF) and transforming growth factor α (TGFα). This
binding then activates downstream gene pathways such
as the mitogen-activated protein kinase (MAPK), protein
kinase B (Akt), and c-Jun N-terminal kinase (JNK) path-
ways, to lead to DNA synthesis and cell proliferation,
migration, and invasion [27]. Clinically, EGFR mutation
and aberrant overexpression may lead to human car-
cinogenesis and tumor progression, including esophageal
cancer [14]. For the past decade, targeting EGFR activity
using gefitinib and erlotinib has been used successfully to
treat certain lung and colorectal cancer patients [28]. Thus,
such treatment may extend to esophageal cancer patients
with high EGFR expression and provide a survival benefit.
Conclusions
In summary, in the present study we found that EGFR
expression was associated with tumor invasion, lymph
node status, number of lymph node metastases, and UICC
TNM staging in ESCC patients. This study also showed
that the OS and DFS rates were significantly lower in
ESCC patients with high EGFR expression than in those
with low EGFR expression. The multivariate analysis indi-
cated that EGFR expression and lymph node metastasis
were independent factors for predicting ESCC prognosis.
Furthermore, ESCC patients at stage T2-3N0M0 could be
considered to have better or poor prognosis based on the
EGFR expression level in tissues. Therefore, our current
data suggest that EGFR expression should be included as a
supplement to UICC staging, especially for T2/T3N0M0
and lymph node-negative patients.
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